Lyra Therapeutics, Inc. LYRA
0.20
0.17
566.67%
as of 25 Sep
- Market cap
- $870.0K
- P/E
- 0.0×
Follow LYRA
| Older periods | Mar '25 | Jun '25 | Sep '25 | Dec '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(195.46%) | (238.26%) | (404.48%) | (6,594.98%) | |
| (80.40%) | (52.78%) | (53.81%) | (56.45%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(335.41%) | (184.42%) | (224.73%) | (370.71%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(42.88) | (32.02) | (19.31) | (18.61) | |
Free Cash Flow |
(56.40) | (43.20) | (34.14) | (28.90) | |
Capital Expenditures |
— | (0.19) | 0.01 | (0.04) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(158.39%) | (136.94%) | (192.62%) | (557.55%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,565.74% | 2,889.61% | 3,399.17% | 4,625.88% | |
Selling, General and Administrative Expense of Revenue |
1,345.65% | 1,858.18% | 2,102.17% | 2,899.50% | |
Share Based Compensation of Revenue |
453.92% | 671.30% | 618.67% | 586.68% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.71 | 1.11 | 1.04 | 1.00 | |
Depreciation/Fixed assets |
(0.69) | (0.19) | 0.22 | 0.44 | |
Capex/Depreciation |
0.00 | 0.86 | 0.02 | (0.09) | |
Revenue per Share |
0.90 | 0.57 | 0.34 | 0.26 | |
Operating CF per Share |
(42.88) | (31.88) | (19.31) | (18.58) | |
Capex per Share |
0.00 | (0.14) | 0.00 | (0.03) | |
Capex to Sales |
0.00 | 0.25 | (0.01) | 0.10 | |
Net Profit Margin |
(6,711.39%) | (5,043.64%) | (5,491.17%) | (7,266.08%) |
Columns are period end dates